Arcutis Biotherapeutics announced the appointment of Dr. Robert Scott to its Board of Directors, effective October 23, 2026. The company's board was expanded from ten to eleven members to facilitate the appointment. Dr. Scott is a veteran pharmaceutical executive, having previously served as Chief Medical Officer at AbbVie and held senior development roles at Amgen, bringing significant industry experience to the board.
Key Details
- Appointment: Dr. Scott was appointed as a Class II director with a term expiring at the 2028 annual meeting and will also serve on the Nominating and Corporate Governance Committee.
- Experience: He previously served as Chief Medical Officer and Head of Development at AbbVie from April 2016 to April 2020, and as Vice President of Global Development at Amgen from 2010 to 2016.
- Compensation: Dr. Scott will receive an initial stock option for 20,507 shares, and is eligible for a prorated annual equity award valued at approximately $350,000 and annual cash retainers totaling $55,000.